HC Wainwright Increases Tyra Biosciences (NASDAQ:TYRA) Price Target to $30.00

Tyra Biosciences (NASDAQ:TYRAGet Free Report) had its price objective increased by analysts at HC Wainwright from $25.00 to $30.00 in a research report issued on Monday, Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price target suggests a potential upside of 38.63% from the stock’s previous close.

Several other equities research analysts have also recently issued reports on the stock. Oppenheimer raised their price target on shares of Tyra Biosciences from $25.00 to $33.00 and gave the stock an “outperform” rating in a research note on Thursday, September 19th. Wedbush restated an “outperform” rating and set a $28.00 target price on shares of Tyra Biosciences in a research report on Thursday, August 8th. Finally, Piper Sandler assumed coverage on shares of Tyra Biosciences in a research note on Thursday, August 15th. They issued an “overweight” rating and a $33.00 target price for the company. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, Tyra Biosciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $27.80.

Read Our Latest Research Report on Tyra Biosciences

Tyra Biosciences Stock Performance

TYRA stock opened at $21.64 on Monday. The stock’s 50 day moving average price is $21.80 and its 200 day moving average price is $19.12. The firm has a market cap of $1.14 billion, a P/E ratio of -12.88 and a beta of 1.01. Tyra Biosciences has a 1 year low of $10.38 and a 1 year high of $25.14.

Tyra Biosciences (NASDAQ:TYRAGet Free Report) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.41) by $0.09. On average, research analysts predict that Tyra Biosciences will post -1.53 earnings per share for the current year.

Insider Activity

In other news, CEO Todd Harris sold 10,092 shares of the business’s stock in a transaction on Monday, September 23rd. The shares were sold at an average price of $24.13, for a total transaction of $243,519.96. Following the completion of the sale, the chief executive officer now directly owns 1,479,528 shares of the company’s stock, valued at $35,701,010.64. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders sold a total of 16,890 shares of company stock valued at $408,444 in the last 90 days. 15.40% of the stock is currently owned by insiders.

Institutional Trading of Tyra Biosciences

A number of institutional investors have recently modified their holdings of the company. Rhumbline Advisers raised its holdings in Tyra Biosciences by 12.3% in the second quarter. Rhumbline Advisers now owns 23,572 shares of the company’s stock valued at $377,000 after buying an additional 2,574 shares during the period. Wellington Management Group LLP increased its position in shares of Tyra Biosciences by 8.8% in the fourth quarter. Wellington Management Group LLP now owns 102,436 shares of the company’s stock worth $1,419,000 after acquiring an additional 8,324 shares in the last quarter. SG Americas Securities LLC purchased a new position in shares of Tyra Biosciences in the 3rd quarter valued at $311,000. Bank of New York Mellon Corp lifted its holdings in shares of Tyra Biosciences by 32.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 58,087 shares of the company’s stock valued at $929,000 after acquiring an additional 14,352 shares in the last quarter. Finally, HighVista Strategies LLC purchased a new stake in Tyra Biosciences during the 2nd quarter worth $257,000. Hedge funds and other institutional investors own 84.14% of the company’s stock.

About Tyra Biosciences

(Get Free Report)

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.

Further Reading

Analyst Recommendations for Tyra Biosciences (NASDAQ:TYRA)

Receive News & Ratings for Tyra Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyra Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.